OGN trades 16.1% above Wall Street's consensus target of $11.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OGN achieves its forward estimates and maintains a stable P/E multiple of 4.0x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 29, 2026, Organon & Co. (OGN) has a Wall Street consensus price target of $11.33, based on estimates from 9 covering analysts. With the stock currently trading at $13.50, this represents a potential downside of -16.1%. The company has a market capitalization of $3.55B.
Analyst price targets range from a low of $8.00 to a high of $14.00, representing a 53% spread in expectations. The median target of $12.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, OGN trades at a trailing P/E of 18.8x and forward P/E of 4.0x. Analysts expect EPS to grow +263.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $40.32, with bear and bull scenarios of $25.40 and $53.13 respectively. Model confidence stands at 38/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PFEPfizer Inc. | $138.1B | $24.29 | $26.75 | +10.2% | Hold | 8.2x | 39 |
VTRSViatris Inc. | $19.0B | $16.33 | $17.40 | +6.6% | Hold | 6.6x | 13 |
ABBVAbbVie Inc. | $444.4B | $251.52 | $258.00 | +2.6% | Buy | 17.7x | 41 |
HLNHaleon plc | $41.1B | $9.24 | $10.20 | +10.4% | Buy | 22.0x | 4 |
TEVATeva Pharmaceutical Industries Limited | $38.7B | $33.21 | $40.00 | +20.4% | Buy | 15.2x | 46 |
PRGOPerrigo Company plc | $1.4B | $9.95 | $36.20 | +263.8% | Hold | 4.7x | 36 |
EVAXEvaxion Biotech A/S | $20M | $3.09 | — | — | — | — | — |
ANIPANI Pharmaceuticals, Inc. | $1.9B | $84.50 | $124.00 | +46.7% | Buy | 9.0x | 10 |
MCKMcKesson Corporation | $91.8B | $763.51 | $994.86 | +30.3% | Buy | 17.3x | 31 |
CAHCardinal Health, Inc. | $56.0B | $237.92 | $253.38 | +6.5% | Buy | 22.1x | 33 |
Quick answers to the most common questions about buying OGN stock.
OGN's consensus price target is $11.33, -16.1% below the current price of $13.5. The 9 analysts tracking OGN see downside risk at present valuations.
OGN has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $11.33 implies -16.1% downside from current levels.
With a forward P/E of 3.974x, OGN trades at a relatively low valuation. The consensus target of $11.33 implies -16.1% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $14 for OGN, while the most conservative target is $8. The consensus of $11.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $53 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
OGN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 4 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OGN stock forecast based on 9 Wall Street analysts shows a consensus price target of $11.33, with estimates ranging from $8 (bear case) to $14 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $40, with bear/bull scenarios of $25/$53.
Our quantitative valuation model calculates OGN's fair value at $40 (base case), with a bear case of $25 and bull case of $53. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 38/100.
OGN trades at a forward P/E ratio of 4.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on OGN, with 3 Sell ratings and a price target of $11.33 (-16.1% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OGN analyst price targets range from $8 to $14, a 53% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.33 consensus represents the middle ground. Our model's $25-$53 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.